Literature DB >> 26832770

Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas.

Anne M Schultheis1, Charlotte K Y Ng1, Maria R De Filippo1, Salvatore Piscuoglio1, Gabriel S Macedo1, Sonia Gatius1, Belen Perez Mies1, Robert A Soslow1, Raymond S Lim1, Agnes Viale1, Kety H Huberman1, Jose C Palacios1, Jorge S Reis-Filho1, Xavier Matias-Guiu2, Britta Weigelt2.   

Abstract

Synchronous early-stage endometrioid endometrial carcinomas (EECs) and endometrioid ovarian carcinomas (EOCs) are associated with a favorable prognosis and have been suggested to represent independent primary tumors rather than metastatic disease. We subjected sporadic synchronous EECs/EOCs from five patients to whole-exome massively parallel sequencing, which revealed that the EEC and EOC of each case displayed strikingly similar repertoires of somatic mutations and gene copy number alterations. Despite the presence of mutations restricted to the EEC or EOC in each case, we observed that the mutational processes that shaped their respective genomes were consistent. High-depth targeted massively parallel sequencing of sporadic synchronous EECs/EOCs from 17 additional patients confirmed that these lesions are clonally related. In an additional Lynch Syndrome case, however, the EEC and EOC were found to constitute independent cancers lacking somatic mutations in common. Taken together, sporadic synchronous EECs/EOCs are clonally related and likely constitute dissemination from one site to the other.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26832770      PMCID: PMC4909128          DOI: 10.1093/jnci/djv427

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  40 in total

1.  Staging classification for cancer of the ovary, fallopian tube, and peritoneum.

Authors:  Jaime Prat
Journal:  Int J Gynaecol Obstet       Date:  2013-10-22       Impact factor: 3.561

2.  FIGO staging for carcinoma of the vulva, cervix, and corpus uteri.

Authors: 
Journal:  Int J Gynaecol Obstet       Date:  2014-02-22       Impact factor: 3.561

Review 3.  Clonality in gynecologic neoplasms: is it time to reevaluate clonality studies in gynecologic neoplasms? Is it possible to confirm multicentricity with clonality studies?

Authors:  Elvio G Silva; Xavier Matias-Guiu
Journal:  Ann Diagn Pathol       Date:  2012-03-13       Impact factor: 2.090

4.  Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.

Authors:  Melissa K McConechy; Michael S Anglesio; Steve E Kalloger; Winnie Yang; Janine Senz; Christine Chow; Alireza Heravi-Moussavi; Gregg B Morin; Anne-Marie Mes-Masson; Mark S Carey; Jessica N McAlpine; Janice S Kwon; Leah M Prentice; Niki Boyd; Sohrab P Shah; C Blake Gilks; David G Huntsman
Journal:  J Pathol       Date:  2011-03-07       Impact factor: 7.996

5.  beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas.

Authors:  G Moreno-Bueno; C Gamallo; L Pérez-Gallego; J C de Mora; A Suárez; J Palacios
Journal:  Diagn Mol Pathol       Date:  2001-06

6.  Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis.

Authors:  Julie A Irving; Lluis Catasús; Alberto Gallardo; Elena Bussaglia; Marisa Romero; Xavier Matias-Guiu; Jaime Prat
Journal:  Hum Pathol       Date:  2005-06       Impact factor: 3.466

7.  Predicting clinical outcome in patients diagnosed with synchronous ovarian and endometrial cancer.

Authors:  Susan J Ramus; Karim Elmasry; Zhiyuan Luo; Alex Gammerman; Karen Lu; Ayse Ayhan; Naveena Singh; W Glenn McCluggage; Ian J Jacobs; John C Whittaker; Simon A Gayther
Journal:  Clin Cancer Res       Date:  2008-09-15       Impact factor: 12.531

8.  Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands.

Authors:  Ilan Weinreb; Salvatore Piscuoglio; Luciano G Martelotto; Daryl Waggott; Charlotte K Y Ng; Bayardo Perez-Ordonez; Nicholas J Harding; Javier Alfaro; Kenneth C Chu; Agnes Viale; Nicola Fusco; Arnaud da Cruz Paula; Caterina Marchio; Rita A Sakr; Raymond Lim; Lester D R Thompson; Simion I Chiosea; Raja R Seethala; Alena Skalova; Edward B Stelow; Isabel Fonseca; Adel Assaad; Christine How; Jianxin Wang; Richard de Borja; Michelle Chan-Seng-Yue; Christopher J Howlett; Anthony C Nichols; Y Hannah Wen; Nora Katabi; Nicholas Buchner; Laura Mullen; Thomas Kislinger; Bradly G Wouters; Fei-Fei Liu; Larry Norton; John D McPherson; Brian P Rubin; Blaise A Clarke; Britta Weigelt; Paul C Boutros; Jorge S Reis-Filho
Journal:  Nat Genet       Date:  2014-09-21       Impact factor: 38.330

9.  Subclonal diversification of primary breast cancer revealed by multiregion sequencing.

Authors:  Lucy R Yates; Moritz Gerstung; Stian Knappskog; Christine Desmedt; Gunes Gundem; Peter Van Loo; Turid Aas; Ludmil B Alexandrov; Denis Larsimont; Helen Davies; Yilong Li; Young Seok Ju; Manasa Ramakrishna; Hans Kristian Haugland; Peer Kaare Lilleng; Serena Nik-Zainal; Stuart McLaren; Adam Butler; Sancha Martin; Dominic Glodzik; Andrew Menzies; Keiran Raine; Jonathan Hinton; David Jones; Laura J Mudie; Bing Jiang; Delphine Vincent; April Greene-Colozzi; Pierre-Yves Adnet; Aquila Fatima; Marion Maetens; Michail Ignatiadis; Michael R Stratton; Christos Sotiriou; Andrea L Richardson; Per Eystein Lønning; David C Wedge; Peter J Campbell
Journal:  Nat Med       Date:  2015-06-22       Impact factor: 53.440

10.  Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis.

Authors:  Roland F Schwarz; Charlotte K Y Ng; Susanna L Cooke; Scott Newman; Jillian Temple; Anna M Piskorz; Davina Gale; Karen Sayal; Muhammed Murtaza; Peter J Baldwin; Nitzan Rosenfeld; Helena M Earl; Evis Sala; Mercedes Jimenez-Linan; Christine A Parkinson; Florian Markowetz; James D Brenton
Journal:  PLoS Med       Date:  2015-02-24       Impact factor: 11.069

View more
  57 in total

1.  The genetic landscape of endometrial clear cell carcinomas.

Authors:  Deborah F DeLair; Kathleen A Burke; Pier Selenica; Raymond S Lim; Sasinya N Scott; Sumit Middha; Abhinita S Mohanty; Donavan T Cheng; Michael F Berger; Robert A Soslow; Britta Weigelt
Journal:  J Pathol       Date:  2017-09-05       Impact factor: 7.996

2.  Somatic genetic alterations in synchronous and metachronous low-grade serous tumours and high-grade carcinomas of the adnexa.

Authors:  Rajmohan Murali; Pier Selenica; David N Brown; R Keira Cheetham; Raghu Chandramohan; Nidia L Claros; Nancy Bouvier; Donavan T Cheng; Robert A Soslow; Britta Weigelt; W Glenn McCluggage
Journal:  Histopathology       Date:  2019-01-15       Impact factor: 5.087

3.  The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma.

Authors:  Ian G Campbell; Kylie L Gorringe; Tanjina Kader; Kenneth Elder; Magnus Zethoven; Timothy Semple; Prue Hill; David L Goode; Niko Thio; Dane Cheasley; Simone M Rowley; David J Byrne; Jia-Min Pang; Islam M Miligy; Andrew R Green; Emad A Rakha; Stephen B Fox; G Bruce Mann
Journal:  NPJ Breast Cancer       Date:  2020-03-12

Review 4.  Fertility-sparing for young patients with gynecologic cancer: How MRI can guide patient selection prior to conservative management.

Authors:  Sinead H McEvoy; Stephanie Nougaret; Nadeem R Abu-Rustum; Hebert Alberto Vargas; Elizabeth A Sadowski; Christine O Menias; Fuki Shitano; Shinya Fujii; Ramon E Sosa; Joanna G Escalon; Evis Sala; Yulia Lakhman
Journal:  Abdom Radiol (NY)       Date:  2017-10

5.  Risk-based stratification of carcinomas concurrently involving the endometrium and ovary.

Authors:  Gulisa Turashvili; Natalia R Gómez-Hidalgo; Jessica Flynn; Mithat Gonen; Mario M Leitao; Robert A Soslow; Rajmohan Murali
Journal:  Gynecol Oncol       Date:  2018-11-06       Impact factor: 5.482

6.  Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Authors:  A Oaknin; R Guarch; P Barretina; D Hardisson; A González-Martín; X Matías-Guiu; A Pérez-Fidalgo; B Vieites; I Romero; J Palacios
Journal:  Clin Transl Oncol       Date:  2017-08-16       Impact factor: 3.405

Review 7.  A guided tour of selected issues pertaining to metastatic carcinomas involving or originating from the gynecologic tract.

Authors:  Robert A Soslow; Rajmohan Murali
Journal:  Semin Diagn Pathol       Date:  2017-11-20       Impact factor: 3.464

8.  Molecular profiling and molecular classification of endometrioid ovarian carcinomas.

Authors:  Paulina Cybulska; Arnaud Da Cruz Paula; Jill Tseng; Mario M Leitao; Ali Bashashati; David G Huntsman; Tayyebeh M Nazeran; Carol Aghajanian; Nadeem R Abu-Rustum; Deborah F DeLair; Sohrab P Shah; Britta Weigelt
Journal:  Gynecol Oncol       Date:  2019-07-21       Impact factor: 5.482

9.  Contralateral breast cancers: Independent cancers or metastases?

Authors:  Colin B Begg; Irina Ostrovnaya; Felipe C Geyer; Anastasios D Papanastasiou; Charlotte K Y Ng; Rita A Sakr; Jonine L Bernstein; Kathleen A Burke; Tari A King; Salvatore Piscuoglio; Audrey Mauguen; Irene Orlow; Britta Weigelt; Venkatraman E Seshan; Monica Morrow; Jorge S Reis-Filho
Journal:  Int J Cancer       Date:  2017-09-28       Impact factor: 7.396

10.  Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations.

Authors:  Elena Guerini-Rocco; Salvatore Piscuoglio; Charlotte K Y Ng; Felipe C Geyer; Maria R De Filippo; Carey A Eberle; Muzaffar Akram; Nicola Fusco; Shu Ichihara; Rita A Sakr; Yasushi Yatabe; Anne Vincent-Salomon; Emad A Rakha; Ian O Ellis; Y Hannah Wen; Britta Weigelt; Stuart J Schnitt; Jorge S Reis-Filho
Journal:  J Pathol       Date:  2016-04       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.